<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854761</url>
  </required_header>
  <id_info>
    <org_study_id>CS-102</org_study_id>
    <nct_id>NCT02854761</nct_id>
  </id_info>
  <brief_title>Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)</brief_title>
  <official_title>Phase I Safety and Tolerability Study of EF-022 in Adult Subjects With Recurrent Respiratory Papillomatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Efranat Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Efranat Ltd.</source>
  <brief_summary>
    <textblock>
      This study evaluates the safety and tolerability of the investigational drug EF-022 in the&#xD;
      treatment of adult patients with Recurrent Respiratory Papillomatosis (RRP). Patients will be&#xD;
      administered EF-022, either intramuscular or subcutaneous, for a period of 6 months.&#xD;
      Preliminary effect of the drug on the disease will be evaluated by following the number and&#xD;
      severity of the lesions in the respiratory tract and the effect on voice changes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The etiology of RRP is associated with local immune suppression at disease-involved sites.&#xD;
&#xD;
      EF-022, a Vitamin D-Binding protein Macrophage Activating Factor, modulates the innate arm of&#xD;
      the immune system to alleviate immune suppression. The investigators hypothesize that EF-022&#xD;
      may modulate the immune response in a manner that might slow down or even prevent disease&#xD;
      progression.&#xD;
&#xD;
      Adult subjects will be treated weekly with EF-022 for a period of 6 months by either&#xD;
      intramuscular or subcutaneous administration.&#xD;
&#xD;
      The primary objective of the study is to evaluate the safety and tolerability of EF-022&#xD;
      administered to adult subjects with recurrent respiratory papillomatosis either IM or SC.&#xD;
&#xD;
      The main response assessment will be performed over the 6 months period by:&#xD;
&#xD;
        -  Evaluating lesion size and/or number of disease-involved sites by Coltera-Derkay score&#xD;
&#xD;
        -  Assessment of degree of voice disorder using the VHI-10 score&#xD;
&#xD;
        -  Symptomatic assessment of dyspnea/stridor&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CTCAE v.4.03 criteria will constitute the primary safety endpoints to be monitored throughout this study</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Recurrent Respiratory Papillomatosis</condition>
  <arm_group>
    <arm_group_label>SC administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous (SC) administration of 500 ng of EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly, for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular (IM) adminstration of 500 ng EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)</intervention_name>
    <arm_group_label>IM administration</arm_group_label>
    <arm_group_label>SC administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with documented diagnosis of recurrent respiratory papillomatosis&#xD;
&#xD;
          2. Patients with measurable disease&#xD;
&#xD;
          3. Patients presenting at least one of the following severity criteria: Derkay score ≥ 8&#xD;
             , Voice handicap index (VHI) ≥11&#xD;
&#xD;
          4. Adult male and female subjects, age of 18 and above (≥18 yrs)&#xD;
&#xD;
          5. Patients with documentation on number of debulking procedures done during past 12&#xD;
             months&#xD;
&#xD;
          6. Estimated expectancy time for next debulking procedure must be at least 3 months.&#xD;
&#xD;
          7. Must be at least 4 weeks (&gt;4 weeks) since last treatment including cytotoxic therapy,&#xD;
             biological or immunotherapy, anti-viral therapy, molecularly targeted therapy or&#xD;
             steroid treatment.&#xD;
&#xD;
          8. Must be at least 2 weeks (&gt;2weeks) since last NSAID treatment.&#xD;
&#xD;
          9. Must have adequately recovered (to at least Grade 1 level) from adverse effects of&#xD;
             prior therapies.&#xD;
&#xD;
         10. Female of child bearing potential must have a negative pregnancy test and must be&#xD;
             practicing an effective method of birth control&#xD;
&#xD;
         11. Patients or their guardians must sign an informed consent indicating that they are&#xD;
             aware of the investigational nature of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient on concurrent steroids or anti-inflammatory non steroid treatment.&#xD;
&#xD;
          2. Active autoimmune disease&#xD;
&#xD;
          3. Known major immunodeficiency&#xD;
&#xD;
          4. Known to be Positive for HIV, Hepatitis B surface antigen, Hepatitis C antibody&#xD;
&#xD;
          5. Have absolute neutrophil counts below 1.5X 10^9/L&#xD;
&#xD;
          6. Hemoglobin below 10.0 g/dL&#xD;
&#xD;
          7. White blood cell counts below 3.5X10^9/L.&#xD;
&#xD;
          8. Granulocytes below 1.5X10^9/L.&#xD;
&#xD;
          9. Have Platelets below 100 X 10^9/L&#xD;
&#xD;
         10. Abnormal renal function with creatinine above 1.5X the upper limit of normal (ULN)&#xD;
&#xD;
         11. Abnormal liver function tests with bilirubin above 1.5X the ULN, AST and ALT above 2.5&#xD;
             X ULN.&#xD;
&#xD;
         12. Patients with active cardiovascular disease under continuous treatment&#xD;
&#xD;
         13. Patients with associated malignancy currently receiving chemotherapy and/or radiation.&#xD;
&#xD;
         14. Female adult patients that are pregnant, nursing or plan to nurse during and up to 12&#xD;
             months of treatment period.&#xD;
&#xD;
         15. Subjects receiving another investigational drug.&#xD;
&#xD;
         16. Patients with concurrent or history of malignancy within 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Myriam Golembo, PhD</last_name>
    <phone>972-8-9724972</phone>
    <email>myriam.golembo@efranat.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Uri Yogev</last_name>
    <phone>972-8-9724972</phone>
    <email>uri.yogev@efranat.com</email>
  </overall_contact_backup>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

